Heat Biologics could be a winner in upcoming months
Heat Biologics Inc.(HTBX) currently trades at $0.57 and has fallen by 2% in the past 24 hours. Heat Biologics had previously announced that it was developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines.
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because Heat has joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts. The high forecast for Heat Biologics Inc. is $5 and the low is $2. Notably, the company’s market cap is $36.90 million with a 52 week high of $1.29 and a 52 week low of $0.20.